Effects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria
Open Access
- 26 September 2023
- journal article
- research article
- Published by Wiley in Mediators of Inflammation
- Vol. 2023, 1-6
Abstract
The mechanism of action of omalizumab in urticaria is still not literally known. This study examines the serum values of substance P (SP), calcitonin gene-related peptide (CGRP), neuropeptide Y (NPY), and interleukin-31 (IL-31) in patients using omalizumab. In this study, 30 patients with chronic spontaneous urticaria (CSU) who were going to be treated with omalizumab and 20 healthy volunteers took part. Demographic data, clinical data, and disease activity scores were noted. For serum SP, CGRP, NPY, and IL-31 values, 10 mL of blood were taken from the patients before starting the treatment, 3 months after the treatment, at the end of the 6th month, and from healthy volunteers all at once. The change in values measured at baseline, 3rd month, and 6th month was analyzed by the Friedman Test. The Mann–Whitney U test was used to compare the parameters obtained from the patients and control groups. The significance level was set at . SP, CGRP, NPY, and IL-31 values were all statistically significantly lower in the CSU patient group compared to the control group. After treatment, the levels of SP and CGRP in the serum went up, and the levels of serum IL-31 went down. These changes were statistically significant. This study supports the view that omalizumab does not only affect IgE receptors but also affects mast cells through other mechanisms. According to our knowledge, this is the first study to show that omalizumab therapy and serum CGRP levels are related.Keywords
Funding Information
- Gaziantep Üniversitesi (TF.UT.22.05)
This publication has 22 references indexed in Scilit:
- Substance P Is Upregulated in the Serum of Patients with Chronic Spontaneous UrticariaJournal of Investigative Dermatology, 2014
- Interleukin-31 promotes helper T cell type-2 inflammation in children with allergic rhinitisPediatric Research, 2014
- Effects of loratadine and cetirizine on serum levels of neuropeptides in patients with chronic urticariaInternational Journal of Dermatology, 2014
- Calcitonin gene‐related peptide and vascular endothelial growth factor are expressed in lesional but not uninvolved skin in chronic spontaneous urticariaClinical & Experimental Allergy, 2014
- Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patientsJournal of Allergy and Clinical Immunology, 2013
- Signaling by IL-31 and functional consequencesEuropean Journal of Cell Biology, 2012
- Increased levels of serum IL‐31 in chronic spontaneous urticaria*Experimental Dermatology, 2010
- Correlation of IL-31 serum levels with severity of atopic dermatitisJournal of Allergy and Clinical Immunology, 2008
- Neuropeptides activate human mast cell degranulation and chemokine productionImmunology, 2008
- Cutaneous responses to substance P and calcitonin gene‐related peptide in chronic urticaria: the effect of cetirizine and dimethindeneAllergy, 1999